+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pneumonia Therapeutics Market by Therapy Type (Adjunctive Therapies, Anti Infectives, Biologics), Route Of Administration (Inhalation, Intravenous, Oral), Distribution Channel, Patient Age Group, Pathogen Type, Indication Type - Global Forecast 2025-2030- Product Image
Pneumonia Therapeutics Market by Therapy Type (Adjunctive Therapies, Anti Infectives, Biologics), Route Of Administration (Inhalation, Intravenous, Oral), Distribution Channel, Patient Age Group, Pathogen Type, Indication Type - Global Forecast 2025-2030- Product Image
Sale

Pneumonia Therapeutics Market by Therapy Type (Adjunctive Therapies, Anti Infectives, Biologics), Route Of Administration (Inhalation, Intravenous, Oral), Distribution Channel, Patient Age Group, Pathogen Type, Indication Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888889
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The pneumonia therapeutics market is advancing rapidly, shaped by scientific innovation, changing clinical demands, and evolving global health priorities. This market analysis equips stakeholders with strategic clarity to navigate emerging trends, evolving therapies, and dynamic regulatory environments.

Market Snapshot: Pneumonia Therapeutics

The Pneumonia Therapeutics Market grew from USD 16.64 billion in 2024 to USD 18.19 billion in 2025. It is expected to continue growing at a CAGR of 9.02%, reaching USD 27.96 billion by 2030. The sector is experiencing transformation driven by rising disease burden, technological advancements, and evolving patient demographics. Rising incidence of bacterial, viral, and atypical pneumonia strains are influencing both commercial investment and public health policy, while complexity in treatment and reimbursement is reshaping regional and global market strategies.

Scope & Segmentation

  • Therapy Types: Adjunctive therapies such as corticosteroids and nebulizers, anti-infectives covering antibiotics (aminoglycosides, beta lactams, macrolides, quinolones, tetracyclines), antifungals, antivirals, biologics including immune modulators and monoclonal antibodies, supportive therapies comprising fluid management, mechanical ventilation, and oxygen therapy.
  • Route of Administration: Inhalation, intravenous, and oral modalities align with severity and patient setting.
  • Distribution Channels: Hospital, online, and retail pharmacies ensure accessible product delivery across all care settings.
  • Patient Age Groups: Adult, geriatric, and pediatric populations, each with distinct dosing and management considerations.
  • Pathogen Types: Coverage includes atypical (Chlamydophila, Legionella, Mycoplasma), bacterial, fungal, and viral organisms.
  • Indication Types: Community-acquired, hospital-acquired, and ventilator-associated pneumonia provide differentiation for development and market positioning.
  • Geographic Regions: Americas (notably United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, South Africa, and others), and Asia-Pacific (comprising China, India, Japan, Australia, South Korea, and others).
  • Company Coverage: Analysis includes Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Johnson & Johnson, Novartis AG, AstraZeneca plc, Bayer AG, Teva Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories Ltd.

Key Takeaways from the Pneumonia Therapeutics Market

  • Market momentum is generated by advancements in diagnostics such as rapid PCR and next-generation sequencing, enabling targeted therapies and faster clinical response.
  • Antimicrobial resistance is spurring development of novel antibiotic classes, host immune modulators, and inhaled formulations focusing on personalized approaches over uniform regimens.
  • Strategic collaborations between pharmaceutical, diagnostic, and clinical research organizations are expanding integrated care solutions, driving innovation beyond standalone drug products.
  • Patient stratification is increasingly pivotal; pediatric, adult, and geriatric populations require nuanced treatment strategies, supported by corresponding formulation and dosing options.
  • Regional adoption hinges on diverse healthcare infrastructures: developed markets emphasize reimbursement systems and biologics, while emerging markets prioritize affordable delivery platforms and local manufacturing.
  • Public health initiatives and commercial incentives combine to promote investment in innovative pneumonia therapies, balancing clinical efficacy with economic sustainability.

Tariff Impact: United States Pharmaceutical Landscape

Recent United States pharmaceutical tariffs, implemented in 2025, have introduced challenges related to higher input costs and changing supply chain strategies. Manufacturers are evaluating regional supply models, contract manufacturing, and onshore investments to minimize tariff exposure. The move requires significant operational and capital adjustments across the sector, prompting commercial teams to realign pricing and distribution strategies for pneumonia therapeutics. Value-based contracting and emphasis on outcome-linked reimbursement are emerging as key approaches for sustained market competitiveness and ensuring patient access to critical therapies.

Methodology & Data Sources

The pneumonia therapeutics market research integrates qualitative interviews with industry leaders, secondary scholarly and regulatory review, and quantitative data analysis from proprietary and public health sources. Multi-source validation and cross-functional synthesis underpin robust and actionable insights for decision-makers.

Why This Report Matters

  • Enables executives to optimize pipeline priorities and adapt to shifting reimbursement, regulatory, and supply chain environments.
  • Offers a clear, data-driven view of competitive landscape, segmentation drivers, and evolving regional trends.
  • Supports strategic investment decisions with actionable intelligence spanning technology, operations, and market differentiation.

Conclusion

Integrating diagnostic advances, nuanced segmentation, and evolved market strategies, this report guides decision-makers through a complex pneumonia therapeutics landscape. Organizations equipped with these insights will be best positioned to drive innovation, competitive positioning, and improved patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of novel inhalable antibiotic formulations for multidrug resistant pneumonia treatment
5.2. Regulatory approvals accelerating availability of pediatric pneumonia vaccines with expanded serotype coverage
5.3. Rising adoption of biomarker-guided antibiotic stewardship protocols in hospital acquired pneumonia management
5.4. Investment surge in phage therapy research targeting antibiotic resistant Streptococcus pneumoniae strains
5.5. Integration of artificial intelligence diagnostics for early detection and classification of severe pneumonia cases
5.6. Growing pipeline of monoclonal antibody therapies targeting inflammatory pathways in severe pneumonia patients
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pneumonia Therapeutics Market, by Therapy Type
8.1. Introduction
8.2. Adjunctive Therapies
8.2.1. Corticosteroids
8.2.2. Nebulizers
8.3. Anti Infectives
8.3.1. Antibiotics
8.3.1.1. Aminoglycosides
8.3.1.2. Beta Lactams
8.3.1.3. Macrolides
8.3.1.4. Quinolones
8.3.1.5. Tetracyclines
8.3.2. Antifungals
8.3.3. Antivirals
8.4. Biologics
8.4.1. Immune Modulators
8.4.2. Monoclonal Antibodies
8.5. Supportive Therapies
8.5.1. Fluid Management
8.5.2. Mechanical Ventilation
8.5.3. Oxygen Therapy
9. Pneumonia Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Inhalation
9.3. Intravenous
9.4. Oral
10. Pneumonia Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Pneumonia Therapeutics Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Pneumonia Therapeutics Market, by Pathogen Type
12.1. Introduction
12.2. Atypical
12.2.1. Chlamydophila
12.2.2. Legionella
12.2.3. Mycoplasma
12.3. Bacterial
12.4. Fungal
12.5. Viral
13. Pneumonia Therapeutics Market, by Indication Type
13.1. Introduction
13.2. Community Acquired
13.3. Hospital Acquired
13.4. Ventilator Associated
14. Americas Pneumonia Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Pneumonia Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Pneumonia Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. GlaxoSmithKline plc
17.3.3. Merck & Co., Inc.
17.3.4. Sanofi S.A.
17.3.5. Johnson & Johnson
17.3.6. Novartis AG
17.3.7. AstraZeneca plc
17.3.8. Bayer AG
17.3.9. Teva Pharmaceutical Industries Ltd.
17.3.10. Dr. Reddy’s Laboratories Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PNEUMONIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PNEUMONIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PNEUMONIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. PNEUMONIA THERAPEUTICS MARKET: RESEARCHAI
FIGURE 28. PNEUMONIA THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 29. PNEUMONIA THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 30. PNEUMONIA THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PNEUMONIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 161. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 162. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 163. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 164. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 165. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
TABLE 166. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2030 (USD MILLION)
TABLE 167. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 168. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 169. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 170. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 171. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 172. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 173. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 178. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 179. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
TABLE 180. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
TABLE 181. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
TABLE 182. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2030 (USD MILLION)
TABLE 183. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
TABLE 184. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2030 (USD MILLION)
TABLE 185. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 186. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 187. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 188. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 189. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
TABLE 190. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2030 (USD MILLION)
TABLE 191. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 192. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 193. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 194. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 195. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 196. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 197. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 202. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 203. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
TABLE 204. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
TABLE 205. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
TABLE 206. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2030 (USD MILLION)
TABLE 207. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
TABLE 208. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2030 (USD MILLION)
TABLE 307. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 308. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 309. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 310. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 311. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
TABLE 312. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2030 (USD MILLION)
TABLE 313. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 314. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 315. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 316. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 317. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 318. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 319. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 320.

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Pneumonia Therapeutics market report include:
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Johnson & Johnson
  • Novartis AG
  • AstraZeneca plc
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 18.19 Billion
Forecasted Market Value ( USD ) by 2030 $ 27.96 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Pneumonia Therapeutics - Global Strategic Business Report - Product Image

Pneumonia Therapeutics - Global Strategic Business Report

  • Report
  • 100 Pages
  • Global
From
Anti-infectives Market by Product Type (Antibiotics, Antifungals, Antiparasitics), Indication (Bloodstream Infections, Gastrointestinal Infections, Respiratory Infections), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Anti-infectives Market by Product Type (Antibiotics, Antifungals, Antiparasitics), Indication (Bloodstream Infections, Gastrointestinal Infections, Respiratory Infections), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Bacterial Pneumonia Drug Pipeline Analysis Report 2025 - Product Image

Bacterial Pneumonia Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Pneumonia Therapeutics Global Market Report 2025 - Product Image

Pneumonia Therapeutics Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Community-acquired Pneumonia (CAP) - Pipeline Insight, 2025 - Product Image

Community-acquired Pneumonia (CAP) - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Pneumonia Drug Market

The Pneumonia Drug market is a subset of the larger Respiratory Drugs market. It includes drugs used to treat bacterial, viral, and fungal pneumonia, as well as other respiratory infections. These drugs are typically administered orally, intravenously, or intramuscularly, depending on the severity of the infection. Commonly prescribed drugs include antibiotics, antivirals, antifungals, and corticosteroids. In addition, some drugs are used to reduce inflammation and improve breathing. The Pneumonia Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck, Sanofi, AstraZeneca, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.